Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration

2008 ◽  
Vol 93 (3) ◽  
pp. 305-309 ◽  
Author(s):  
M P Avila ◽  
M E Farah ◽  
A Santos ◽  
J P Duprat ◽  
B W Woodward ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Prospective Study ◽  
Macular Degeneration ◽  
Choroidal Neovascularisation ◽  
Age Related Macular Degeneration ◽  
Short Term ◽  
Subfoveal Choroidal Neovascularisation ◽  
Age Related ◽  
Strontium 90 ◽  
Multicentre Prospective Study

Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration

Eye ◽  
2000 ◽  
Vol 14 (2) ◽  
pp. 155-164 ◽  
Author(s):  
Christina J Flaxel ◽  
Eric J Friedrichsen ◽  
Jodi Osborn Smith ◽  
Steven Christopher Oeinck ◽  
Paul A Blacharski ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Proton Beam ◽  
Choroidal Neovascularisation ◽  
Age Related Macular Degeneration ◽  
Beam Irradiation ◽  
Proton Beam Irradiation ◽  
Subfoveal Choroidal Neovascularisation ◽  
Age Related

scholarly journals The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation

2013 ◽  
Vol 70 (7) ◽  
pp. 660-663
Author(s):  
Dragana Ristic ◽  
Miroslav Vukosavljevic ◽  
Biljana Draganic ◽  
Vesna Cerovic ◽  
Nenad Petrovic ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Ophthalmological Examination ◽  
Short Term ◽  
Age Related ◽  
Early Results ◽  
In The Beginning

Background/Aim. Age-related macular degeneration (AMD) is a leading cause of the loss of central visual acuity in population older than 70 years. We can distinguish wet and dry form of AMD. The aim of the study was to present our early results in treatment of the wet (neovascular) form of AMD with intravitreal administration of bevacizumab. Methods. The study included 39 patients. Each patient underwent a complete ophthalmological examination, fluorescein angiography (FA) and optical coherence tomography (OCT). All the patients received 1.25 mg of intravitreal bevacizumab (0.05 mL of commercial phial of Avastin?). The total of three doses was given with a one-month interval between doses. Results. Among 39 patients, 24 were women and 15 men. The average best corrected visual acuity (BCVA) was improved from 0.09 before the therapy to 0.24 after the administration of all the three doses of bevacizumab (p < 0.001). The average central macular thickness (CMT) measured by OCT was improved from 474 ?m in the beginning to 341 ?m after the administration of all the three doses of the drug (p < 0.001). There were no side effects. Conclusions. Our short-term experience indicates that intravitreal administration of three doses of bevacizumab in one-month intervals between the doses leads to a significant reduction of macular edema and improvement of BCVA in patients with neovascular AMD.

Sign in / Sign up

Export Citation Format

Share Document